Suzhou Industrial Park

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Retrieved on: 
Tuesday, May 31, 2022
AR, CRPC, ICB, Population, 1 Canadian Mechanized Brigade Group Headquarters and Signal Squadron, Renji Hospital, Neoplasm, FGFR1, Breast cancer, Shanghai Jiao Tong University, News, Patient, Environment, Lung cancer, Nature, Headquarters, Editorial, Stomach, Esophageal cancer, Research, Hope, IND, Industry, Prostate cancer, Suzhou Industrial Park, Cancer, BMP, Therapy, HKEX, Discovery, List of Nature Research journals, PDX, B cell, Pancreatic cancer, Growth, Castration, Social conditioning, Process, CEO, Jiaotong University, Pharmaceutical industry, Medical imaging

SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Nature Cancer, an international authoritative journal in oncology field, publishes the results of preclinical studies of Transcenta's first-in-class Gremlin1 targeting antibody (TST003) in the treatment of castration resistant prostate cancer. This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine. Professor John T. Isaacs, an internationally renowned expert in prostate cancer research, wrote an editorial and commented that neutralizing antibodies against Gremlin1 could be a potential treatment for androgen receptor-negative/low prostate cancer.

Key Points: 
  • This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine.
  • In this study, researchers from Transcenta and Shanghai Jiao Tong University investigated the therapeutic potential of anti-Gremlin1 for prostate cancer in an aggressive mouse model of CRPC (Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl GEMM) and patient derived xenograft (PDX), using TST003, a humanized Gremlin1-targeting antibody, and a surrogate antibody generated by Transcenta.
  • The study results revealed that Gremlin1 protein can promote lineage plasticity and drive castration resistance in prostate cancer.
  • The publication of the study results in Nature Cancer speaks for its novelty and clinical translational value.

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

Retrieved on: 
Friday, April 29, 2022
NK, Mab, Endothelium, CAPOX, Patient, FDA, ADCC, Pharmacokinetics, Orphan, High Affinity K+ transporter HAK5, Headquarters, Society, Capecitabine, HKEX, Suzhou Industrial Park, American Society of Clinical Oncology, Therapy, 2021 Essex County Council election, Ministry of Education (Malaysia), Process, CDC, Neoplasm, News, Research, Tolerability, Fucose, Nature, 2 Canadian Mechanized Brigade Group Headquarters and Signal Squadron, Stomach, Phases of clinical research, ICB, Discovery, Survival, Environment, Social conditioning, Pharmaceutical industry, Medical imaging, Vaccine, Safety, Oxaliplatin, McCormick Place

SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology ("2022 ASCO Annual Meeting").

Key Points: 
  • SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology ("2022 ASCO Annual Meeting").
  • The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community.
  • This year's ASCO Annual Meeting will take place both online and in-person (McCormick Place; Chicago, IL) on June 37, 2022.
  • Leveraging advanced bioprocessing technology, the fucose content of TST001 was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of TST001.

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

Retrieved on: 
Tuesday, March 22, 2022
ADCC, Esophageal cancer, Orphan, Therapy, EVP, Social conditioning, Process, China Media Group Headquarters, CDC, Fucose, CMO, Bristol Myers Squibb, Metastasis, Survival, Research, Gallbladder, Environment, HKEX, PD-1, Discovery, Safety, ICB, Stomach, Headquarters, News, Nivolumab, NK, Suzhou Industrial Park, FDA, Nature, Pancreatic cancer, Patient, Pharmaceutical industry, Vaccine

Claudin18.2 is a pan-cancer target and is highly over-expressed in gastric cancer, pancreatic cancer, gallbladder and biliary tract cancer, esophageal cancer, and other tumor types.

Key Points: 
  • Claudin18.2 is a pan-cancer target and is highly over-expressed in gastric cancer, pancreatic cancer, gallbladder and biliary tract cancer, esophageal cancer, and other tumor types.
  • The combination of TST001 with checkpoint inhibitor such as Opdivo could provide greater clinical benefits to patients with locally advanced or metastatic gastric /gastroesophageal junction cancer.
  • We are excited to test the combination of TST001 with Opdivo for the treatment of metastatic gastric / gastroesophageal junction cancer as a new potential treatment option for these patients."
  • TST001 was granted Orphan Drug Designation in the US by FDA for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

Retrieved on: 
Thursday, March 10, 2022
Safety, Trial of the century, Social conditioning, Orphan, ADCC, Research, Therapy, DLT, FDA, EVP, III, Suzhou Industrial Park, Cancer, Vomiting, PRS, Nature, China Media Group Headquarters, News, Anemia, AUC, Cmax, Headquarters, Stomach, CDC, Nausea, Discovery, Patient, Stomach cancer, MTD, HKEX, Pancreatic cancer, Process, CMO, Standard of care, Constipation, Environment, PK, NK, HER2, Fucose, PD-L1, ICB, IGCC, Abdominal distension, AES, Pharmaceutical industry, Medical imaging, Hypoalbuminemia

TST001 demonstrated a roughly linear PK profile as both Cmax and AUC increased proportionally across the dose range following the first dose.

Key Points: 
  • TST001 demonstrated a roughly linear PK profile as both Cmax and AUC increased proportionally across the dose range following the first dose.
  • Post the data cut-off date, additional confirmed PRs were observed at recommended phase 2 dose in the newly enrolled monotherapy expansion cohorts including gastric cancer and pancreatic cancer patients with Claudin18.2 expression.
  • TST001, a high affinity Claudin18.2 humanized antibody, is safe and displayed promising anti-tumor activity in Claudin18.2 over-expressing gastric and pancreatic cancer patients."
  • In recent years, Claudin18.2 has emerged as a promising cancer treatment target for gastric cancer beyond HER2 and PD-L1.

Jiangsu launched 5 tourist routes to explore winter in Charm of Jiangsu

Retrieved on: 
Wednesday, January 26, 2022
Ice Skating Institute, Garden, Tourism, Yang County, The Spring Festival, Hot Springs, Suzhou Industrial Park, Bamboo, Temperament, Movement, The Year of the Tiger, Multimedia, Spring Festival, Food, Winter Olympic Games, Growth, Meat, Tiger, Refrigeration, Painting, Color, CIHA, CSA, Suzhou Zhongnan Center, Silver, Yangtze, Lake Tai, Gold, Humble Administrator's Garden, World Heritage Site, Canglang Pavilion, Snow, Eating, Skiing, Fatigue, Ice, ISI

NANJING, China, Jan. 26, 2022 /PRNewswire/ -- With the coming of the Beijing Winter Olympics, Jiangsu has launched 5 tourist routes with Jiangnan characteristics during the period of the Spring Festival.

Key Points: 
  • NANJING, China, Jan. 26, 2022 /PRNewswire/ -- With the coming of the Beijing Winter Olympics, Jiangsu has launched 5 tourist routes with Jiangnan characteristics during the period of the Spring Festival.
  • Jiangsu welcomes the world tourists to feel the Charm of Jiangsu in winter in 5 different ways, according to the Jiangsu Provincial Department of Culture and Tourism.
  • This place has witnessed the growth of many "ice dancers", promoting the ice and snow movement to boil in "Charm of Jiangsu".
  • With the coming of the Winter Olympic Games and the love of ice and snow, welcome to open another kind of "Charm of Jiangsu" in more ways.

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors

Retrieved on: 
Tuesday, January 18, 2022
Medical Devices, Hospitals, Genetics, Clinical Trials, Stem Cells, Other Health, Biotechnology, General Health, Health, Oncology, Euronext Paris, Vaccination, Forward-looking statement, Patient, Technology, Korea Carbon Capture & Sequestration R&D Center, Potyvirus, R, TNG, Precision medicine, Headquarters, Virus, AMF, IV, Cell, Risk, Suzhou Industrial Park, Pancreatic cancer, Cancer, Center, AstraZeneca, Marketing, Artificial intelligence, Tumor microenvironment, NEC, Neoplasm, Immunotherapy, T-lymphoblastic leukemia/lymphoma, Vaccine, Medical imaging, Pharmaceutical industry, IND, Euronext, Transgene

The collaboration aims to demonstrate the combinations likely synergistic mechanisms to potentiate CAR-T cell therapy.

Key Points: 
  • The collaboration aims to demonstrate the combinations likely synergistic mechanisms to potentiate CAR-T cell therapy.
  • PersonGen will evaluate the efficacy of the combination to eliminate solid tumors in preclinical models.
  • In addition, the high heterogeneity of solid tumors also facilitates immune escape from CAR-T cell therapy.
  • Preclinical studies with TAA06, including pharmacodynamic data have shown superior in vivo and in vitro therapeutic efficacy in solid tumors.

Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts

Retrieved on: 
Wednesday, January 12, 2022
Sepsis, Technology, Mortality, Publication, Disease, Risk, Science, Industrial park, Solution, U.S. Securities and Exchange Commission, Time, Nasdaq, View, Acceleration, Infection, Company, Method, Subclinical infection, Multimedia, Entrepreneurship, Annual report, Suzhou Industrial Park, FDA, Security (finance), Pharmaceutical industry

TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ --Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno System.

Key Points: 
  • TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ --Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno System.
  • The award brings further recognition to the Accelerate Pheno System and will help to defray near-term costs to continue commercialization efforts in China.
  • Accelerate Diagnostics, Inc. is anin vitrodiagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENO TEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
    For more information about the company, its products and technology, or recent publications, visit axdx.com .

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

Retrieved on: 
Wednesday, January 12, 2022
CDC, ICB, Pharmacokinetics, Research, News, Nature, EVP, NK, Discovery, Stomach, HKEX, Social conditioning, CMO, China Media Group Headquarters, IGCC, Fucose, Process, Pancreatic cancer, Suzhou Industrial Park, Tolerability, Headquarters, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Environment, Therapy, ASCO, ADCC, Cancer, Food, FDA, PD-1, Orphan, Pharmaceutical industry, Vaccine, Safety, Patient

Two phase I trials have been ongoing in both US and China since April 2020.

Key Points: 
  • Two phase I trials have been ongoing in both US and China since April 2020.
  • The IGCC poster will present the data of the TST001 dose-escalation part from this ongoing trial.
  • The ASCO GI poster TPS375 will present the design of the US trial as Trial in Progress.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022
SLE, Kidney, Research, Patient, PV, The Company, Twelfth, CD22, China Galaxy Securities, The Group, Lists of companies, NHL, Growth, Pemphigus vulgaris, Lupus, Suzhou Industrial Park, Mab, RA, Company, SM03, Therapy, Asthma, B-cell lymphoma, Internet, Rheumatoid arthritis, Thirteenth, Telecommunication, III, Film, Pharmaceutical industry

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

Xinhua Silk Road: 2021 Global AI Product & Application Expo kicks off in Suzhou to boost dev. of AI industry

Retrieved on: 
Wednesday, September 22, 2021
Huawei, Global, Artificial intelligence, Suzhou Industrial Park, Baidu, Exhibition, Microsoft, AI, SenseTime, Suzhou Zhongnan Center, Technology, IFlytek, Party, Research, Industry, Education, Travel, Medical device, Phosphorus

BEIJING, Sept. 22, 2021 /PRNewswire/ -- The 2021 Global AI Product & Application Expokicked off Thursday in Suzhou of east China's Jiangsu Province, focusing on the latest technological achievements and applications of artificial intelligence (AI).

Key Points: 
  • BEIJING, Sept. 22, 2021 /PRNewswire/ -- The 2021 Global AI Product & Application Expokicked off Thursday in Suzhou of east China's Jiangsu Province, focusing on the latest technological achievements and applications of artificial intelligence (AI).
  • The event will last to September 18, and "AI plus manufacturing", "AI plus medical", "AI plus finance", "AI plus cultural tourism" and other areas with local features of Suzhou will be highlighted.
  • The opening ceremony for the 2021 Global AI Product & Application Expo is held Thursday in Suzhou.
  • The Global AI Product & Application Expo is an important window to display the achievements of China's pilot zones of new-generation AI innovation and development, and has been held in Suzhou for three consecutive years since 2018.